Anti-IL-17, Anti-IL-23 Rxs Show Sustained Psoriasis Control

Both an approved anti-IL-17 therapy and an experimental oral anti-IL-23 therapy appeared to achieve relatively undiminished rates of psoriasis control in extension studies.
Medscape Medical News

source https://www.medscape.com/viewarticle/anti-il-17-anti-il-23-therapies-show-sustained-psoriasis-2024a10004jh?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost